This year ISSDP is hosting/co-producing two conferences in Lisbon from 22-25 November.
Drug Market and Drug Policy Innovation in a Changing World
Tuesday, November 22, 2022.
ISSDP will be holding a one-day, in-person meeting in Lisbon on Tuesday, November 22, 2022 prior to the 2022 Lisbon Addictions Conference featuring:
- Full day of drug policy and drug market research, including presentations by Peter Reuter (USA), Tim Rhodes (UK), Chris Wilkins (New Zealand), Marie Jauffret-Roustide (France), Bernd Werse (Germany), Alison Ritter (Australia), and more.
- Keynote speech by Sarah Larney, Associate Professor in the Department of Family Medicine and Emergency Medicine at the Université de Montréal and Principal Scientist at the Centre de recherche du Centre Hospitalier de l’Université de Montréal. Her research focuses on the epidemiology of injecting drug use and related harms, and identifying avenues to reduce drug-related harms such as overdose, HIV and hepatitis C and bacterial infections. Sarah’s research has contributed to many policy reforms including expanding access to opioid agonist treatment in prison settings and the introduction of US Federal Bureau of Prisons guidelines on hepatitis c screening.
- Panel with policy makers on “What Policy Makers Need to Know”, featuring 1) Hanan Abramovici, Director at Health Canada, 2) João Castel-Branco Goulão, Portuguese National Drugs Coordinator, 3) Mr Alexis Goosdeel, Director of the EMCDDA , 4) Angela Me, Chief of the Research and Trend Analysis Branch, UNODC, 5) Christopher Jones, acting director of the US National Center for Injury Prevention and Control and former senior public health advisor to the White House Office of National Drug Control Policy.
- A panel discussion on drug policy courses (health, criminal justice programs, drug markets, and working professionals).
- Late breaking abstracts covering topics on drug markets, psychedelic policy, harm reduction, and innovative programs and research.
- Dinner with colleagues, the first ISSDP Excellence in Drug Policy Research, and this year’s Franz Trautmann Memorial Speaker, Stijn Hoorens (RAND Europe).
Location & Host: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
(Location on Google Maps)
Additional work from ISSDP investigators will be presented in ISSDP-sponsored thematic track at the 2022 Lisbon Addictions Conference.
To register for the conference, please go to https://issdp.memberclicks.net/pre-lisbon-conference-registration
|Regular Fee (After August 30, 2022)|
Optional Dinner Tuesday Evening with Franz Trautmann Lecturer, Stijn Hoorens (RAND Europe), and ISSDP Research in Excellence Awardee (TBD). Cost for the dinner and lecture is €70 per person (venue TBD). Please register for dinner by September 15, 2022 to ensure space.
Sarah Larney is an Associate Professor in the Department of Family Medicine and Emergency Medicine at the Université de Montréal and a researcher at the Centre de recherche du Centre Hospitalier de l’Université de Montréal. Her research focuses on the epidemiology of injecting drug use and related harms, and opportunities to reduce harms such as overdose, HIV and hepatitis C, and bacterial infections. Arriving in Montreal in February of 2020, much of her current work examines the impact of the COVID pandemic on people who inject drugs and services for this population, such as supervised injecting sites. She is also developing a program of research to integrate sex and gender considerations into hepatitis C elimination efforts. Sarah’s work on hepatitis C in incarcerated populations influenced US Federal Bureau of Prisons guidelines on screening, and her research on opioid agonist treatment has been influential in expanding access to care in prison settings. She completed her PhD at the National Drug and Alcohol Research Centre, University of New South Wales, Sydney, and post-doctoral fellowship in the Division of Infectious Diseases, Alpert Medical School, Brown University.
João Castel-Branco Goulão has served as the Portuguese National Drugs Coordinator since 2005, is the General Director of the Service for Intervention on Addictive Behaviors and Dependencies (Ministry of Health). A medical doctor by profession, João Goulão has over 30 years’ experience regarding drug-related issues, working in this field since 1987 as general practitioner. He was a member of the Portuguese Committee that, in 1999, prepared the report on which the first Portuguese Drug Strategy, which included decriminalization, was based. He has served as the Portuguese representative in the Management Board of the European Monitoring Centre on Drugs and Drug Addiction since 2005, serving as Chairman from 2010 to 2015. He had previously served on the European agency’s Scientific Committee (1997–2002). He chaired the Horizontal Working Party on Drugs of the EU in the first semester of 2021 and is, since 2019, the Chair of the Permanent Correspondents of the Pompidou Group.
Mr Alexis Goosdeel, Director of the EMCDDA. Mr Goosdeel has spent much of his 30-year career working in the field of public health at national, European and international level. He was one of the founders of Modus Vivendi, a Belgian NGO working in the area of harm reduction. Before joining the EMCDDA, he directed Alizés, a Brussels-based, European association working for development and cooperation in public health (1992–99). Mr Goosdeel joined the EMCDDA in 1999 as a project manager working in the area of EU enlargement and international relations. From 2005, he headed the agency’s Reitox and international cooperation unit. In this capacity, he played a central role in: coordinating a network of 30 national drug monitoring centres; preparing EU candidate and potential candidate countries for membership of the EMCDDA; developing cooperation with neighbouring countries to the EU; and nurturing relations with countries beyond the Union (Central Asia, Russia, Latin America). The EMCDDA Management Board elected him as Director in January 2016 for an initial five year term, which the board unanimously voted to extend for another five years. Mr Goosdeel holds a Master’s degree in clinical psychology and a special diploma in advanced management. He is proficient in six languages: French (mother tongue); English, Spanish, Greek, Portuguese and Dutch.
Ms Angela Me is the Chief of the Research and Trend Analysis Branch at the United Nations Office on Drugs and Crime where she oversees global, regional and national research in the areas of drugs and crime. She is responsible for global reference research publications such as the World Drug Report, the Global Report on Trafficking in Persons, the Global Study on Homicide, and the World Wildlife Crime Report. While working for the United Nations since 1995, she has supported countries to improve their statistical and analysis systems, and she has authored, contributed and supervised the production of UN analytical reports, international statistical standards, discussion papers, and inter-governmental documents in the areas of drugs, crime, population, gender, disability, and migration. She has served in the Scientific Committee of the European Agency for Fundamental Rights. As an Italian national, Ms. Me holds a Ph.D. in statistics from the University of Padua in Italy.
Hanan Abramovici is the Director of the Office of Cannabis Science and Surveillance in the Controlled Substances and Cannabis Branch at Health Canada. Since 2010, Hanan has been involved in numerous Canadian federal government monitoring, surveillance, and research activities on cannabis. In 2017, he founded the Office of Cannabis Science and Surveillance (OCSS) at Health Canada. The OCSS provides scientific expertise on a variety of topics related to cannabis to support activities that include surveillance, public education and awareness, policy development and compliance and enforcement actions. The OCSS also monitors and assesses adverse reactions to cannabis; carries out risk assessments on cannabis products; works towards developing cannabis standards; and conducts and fosters scientific research on cannabis to support the objectives of the Cannabis Act to protect public health and safety. Hanan has a Ph.D. in Neuroscience from the University of Ottawa and a M.Sc. in Pharmacology from the University of Toronto.
Christopher Jones, PharmD, DrPH, MPH (CAPT U.S. Public Health Service) is currently serving as the acting director of the National Center for Injury Prevention and Control, where he provides leadership and drives NCIPC’s strategic direction by overseeing the refinement of the scientific research agenda and the coordination on the NCIPC strategic priorities of drug overdose, suicide prevention, and adverse childhood experiences. Prior to joining CDC, Dr. Jones served as the first director of the National Mental Health and Substance Use Policy Laboratory at the Substance Abuse and Mental Health Services Administration (SAMHSA). The Policy Lab is responsible for identifying, coordinating, and facilitating the implementation of policies to improve mental health and substance use prevention, treatment and recovery, and with advancing innovation and the dissemination and adoption of evidence-based practices and programs related to mental health and substance use. Prior to SAMHSA, Dr. Jones served as acting associate deputy assistant secretary for Science and Data Policy and director of the Division of Science Policy in the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health and Human Services (HHS). He has also served as senior advisor in the Office of the Commissioner at the U.S. Food and Drug Administration (FDA), and was assigned to the White House Office of National Drug Control Policy as the senior public health advisor.
He received a Bachelor of Science degree from Reinhardt College, a Doctor of Pharmacy degree from Mercer University, a Master of Public Health degree from New York Medical College, and a Doctor of Public Health in Health Policy from The George Washington University Milken Institute School of Public Health. Dr. Jones is a captain in the U.S. Public Health Service and has authored more than 100 peer-reviewed publications on the topics of substance use, drug overdose, adverse childhood experiences, and mental health.
Stijn Hoorens is a senior research leader at RAND Europe and director of RAND’s Brussels office. He has been working on drugs policy research with colleagues at the RAND Drug Policy Research Center since joining RAND in 2002. Since then, he has contributed to and led numerous studies on the interface of public health, illicit markets and economics. For example, he is currently leading RAND’s contribution to the monitoring and evaluation of the closed supply chain experiment with quality-controlled cannabis cultivation in the Netherlands. Other examples include a study on preventive measures to tackle drug-related organised crime in the Netherlands, developing a method for measuring the size of the European market for illegal tobacco products, an analysis the size and scope of internet-facilitated drug trade, several evaluations of the European drugs strategy and its action plans, a study developing indicators to measure illicit drug markets, supply-reduction efforts, and drug-related crime in the EU and many more. Stijn has been a member of scientific steering committees for various studies and evaluations on cannabis and coffeeshop policy in the Netherlands. Before joining RAND, Stijn held research positions at Delft University of Technology and TNO.
|8:30-9:00||Registration & Coffee|
|9.00–9:30||Welcome & Opening Remarks|
|10.30–11:30||Break Out Sessions|
|11:35 – 12:35||Break Out Sessions|
|13:15 – 13:45||Poster Session|
|13.45–14.45||Break Out Sessions|
|14:50–16:00||Break Out Sessions|
|16:00 -16.15||Coffee break|
|16.15-17:15||What Policy Makers Need to Know About the Science: Input from a Panel of Policy Makers|
|17:15 – 17:30||Closing|
|17:30 – 18:00||Annual Meeting|
|18:00||Break for Dinner|
Confirmed speakers include:
|Eric L. Sevigny||Georgia State University, Department of Criminal Justice & Criminology, Atlanta, GA, USA|
|Peter Reuter||University of Maryland, College Park, Maryland, USA|
|Coleman Drake||University of Pittsburgh
Department of Health Policy and Management
130 De Soto St, Pittsburgh, PA 15261 United States
|Chris Wilkins||Massey University, Auckland, New Zealand|
|Davide Fortin||Sorbonne Economics Centre, Pantheon-Sorbonne University, France|
|Marta Rychert||Massey University, New Zealand|
|Marie Jauffret-Roustide||Inserm, Paris France|
|Gary Potter||Lancaster University Law School, Bowland North, Bailrigg, Lancaster, LA14YN, UK|
|Luca Giommoni||Cardiff University, Cardiff|
|Glenn Sterner||Pennsylvania State University|
|Lee Hoffer||Case Western Reserve University, Ohio|
|Jonas von Hoffmann||Drug Policy Program, CIDE, Aguascalientes Mexico|
|Ediomo-Ubong Nelson||Global Drug Policy Observatory, Swansea University, United Kingdom|
|Winnie Agnew-Pauley||Flinders University, Centre for Crime Policy and Research, Sturt Rd, Bedford Park SA 5042, Australia|
|Vibeke Asmussen Frank||Center for Alcohol and Drug Research, Aarhus University, Bartholins Alle 10, 3., 8000 Aarhus C, Denmark|
|Jasmina Burdzovic Andreas||Department of Alcohol, Tobacco, and Drugs
Norwegian Institute of Public Health
Oslo, NorwayHealth, Developmental and Personality Section
Department of Psychology
University of Oslo
|Silje Louise Dahl||Volda University College|
|Tim Rhodes||London School of Hygiene and Tropical Medicine, UK|
|Caitlin Hughes||Centre for Crime Policy and Research, Flinders University, Australia|
|Rosalie Liccardo Pacula||University of Southern California, Price School of Public Policy and Schaeffer Center USA|
|Greg Midgette||University of Maryland, Department of Criminology and Criminal Justice, College Park, MD, USA|
|Steve Rolles||Transform Drugs Policy Foundation, UK|
|Hagit Bonny-Noach||Senior lecturer in the Department of Criminology -Ariel University & Board member of the Israeli Society of Addiction Medicine (ILSAM)|
|Daniel Bear||Humber College, Toronto, Ontario Canada|
|Bernd Werse||Goethe University, Centre for Drug Research, Frankfurt|
|Jessica Xavier||British Columbia Centre for Disease Control|
|Linn Gjersing||Norwegian Institute of Public Health|
|Greg Los||University of Brighton | Falmer Campus|
|Giulia Zampini||University of Greenwich, London|
|Alex Stevens||University of Kent, Medway, UK|
|Maria Plucinska||University of Lodz, Poland|
|Danica Thanki||UN Office of Drugs and Crime|
|Jaqueline Garcia-Yi||UN Office of Drugs and Crime|
We have limited space for some late breaking abstracts to be presented as a poster presentation. Abstracts will be considered through September 9th, 2022. Notification of acceptance will be made by mid-September. Please submit abstracts including title, author, affiliation, and 250 description in word or PDF format to Seema Choksy Pessar at firstname.lastname@example.org.
Late Breaking Abstract Submission System is now closed.
- Cláudia Costa Storti, Host and Co-Chair (EMCDDA, Lisbon Portugal)
- Rosalie Liccardo Pacula, Co-Chair (University of Southern California, USA)
- Caitlin Hughes (Flinders University, Australia)
- Anne Line Bretteville-Jensen (Norwegian Institute of Public Health, Norway)
- Beau Kilmer (RAND Drug Policy Research Center, USA and Europe)
- Kawal Deep Kour (Director Asia Drug and Alcohol Research Foundation, India)
- Nicola Singleton (Retired, EMCDDA)